Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.36
- Piotroski Score 4.00
- Grade Neutral
- Symbol (OGN)
- Company Organon & Co.
- Price $15.58
- Changes Percentage (0.03%)
- Change $0.01
- Day Low $15.50
- Day High $15.73
- Year High $23.10
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.
- Last Earnings 10/31/2024
- Ex-Dividend for 5/16 Dividend 11/12/2024
- Dividend Payable 12/12/2024
- Today N/A
- Next Earnings (Estimated) 02/13/2025
- Fiscal Year End N/A
- Average Stock Price Target $24.00
- High Stock Price Target $24.00
- Low Stock Price Target $24.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $4.08
- Trailing P/E Ratio 5.09
- Forward P/E Ratio 5.09
- P/E Growth 5.09
- Net Income $1.02 B
Income Statement
Quarterly
Annual
Latest News of OGN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Walmart Cuts DEI Initiatives, Cognition's Approach To AI Coding And More
Forbes' Future of Work newsletter covers insights from Medley Cofounder Edith Cooper on group coaching for leaders, HR leaders' role in startups, and AI coaching. It discusses disruptive technologies,...
By Forbes | 1 day ago -
Andrew Keegan Still Gets Recognized for 10 Things I Hate About You, 25 Years After Its Release (Exclusive)
Kate Hogan, Director of Digital Specials at PEOPLE, also edits Stories to Make You Smile. Andrew Keegan, known for '90s roles, says fans most recognize him as Joey Donner from 10 Things I Hate About Y...
By PEOPLE.com | 2 days ago -
Sydney Sweeney looks unrecognizable in latest role: Actress' best looks over the years
Sydney Sweeney's portrayal of boxer Christy Martin has been emotionally transformative. She expressed gratitude for the experience and the inspiring story. Sweeney's diverse style and powerful presenc...
By Fox News | 2 days ago
